Riggs Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Riggs Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-69	Closed	-$552	–	689
2024 Q4	$552	Hold	69	–	–	﹤0.01%	532
2024 Q3	$1.25K	Hold	69	–	–	﹤0.01%	413
2024 Q2	$711	Hold	69	–	–	﹤0.01%	492
2024 Q1	$733	Buy	+69	New	+$586	﹤0.01%	473

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Riggs Asset Management's PHAT Position: Q1 2025 in Review

Riggs Asset Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 69 shares — an estimated $552 sold.

Riggs Asset Management first reported a position in PHAT in Q1 2024 and held it in 4 quarters. The position peaked at $1.25K in Q3 2024. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

Riggs Asset Management reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Riggs Asset Management sold 69 Phathom Pharmaceuticals shares in Q1 2025, an estimated $552.
Riggs Asset Management first reported a position in Phathom Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Riggs Asset Management's Phathom Pharmaceuticals position peaked at $1.25K in Q3 2024.
137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Riggs Asset Management's 13F filing for Q1 2025, filed 29 Apr 2025.